We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-2.86%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.1B
AUM Growth
-$432M
Cap. Flow
-$290M
Cap. Flow %
-26.37%
Top 10 Hldgs %
65.53%
Holding
227
New
63
Increased
36
Reduced
51
Closed
66

Top Buys

Rank Stock Value
1
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$19.5M
2
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$7.96M
3
MNKD icon
MannKind Corp
MNKD
+$4.94M
4
ESPR
Esperion Therapeutics
ESPR
+$3.17M
5
BNBX
BNB PLUS CORP
BNBX
+$2.81M

Top Sells

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$3.35M
2
BMY icon
Bristol-Myers Squibb
BMY
+$3.2M
3
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$2.96M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$2.32M
5
HURA
TuHURA Biosciences
HURA
+$1.78M

Sector Composition

Rank Sector Weight
1 Healthcare 11.87%
2 Financials 0.19%
3 Industrials 0.07%
4 Consumer Staples 0.03%
5 Materials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NSPR icon
101
InspireMD
NSPR
$32.1M
$555K 0.05%
+165
New +$1.37M
FRTX
102
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$503K 0.05%
+873
New +$575K
FEED
103
ENvue Medical Inc
FEED
$2.09M
$477K 0.04%
+46
New +$460K
VIRX
104
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$461K 0.04%
3,571
-3,390
-49% -$318K
CLVS
105
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$456K 0.04%
67
-1,045
-94% -$73.1K
SSKN
106
DELISTED
Strata Skin Sciences
SSKN
$416K 0.04%
33,511
+12,341
+58% +$172K
FOCL
107
PUT
EDAP TMS S.A.
FOCL
$227M
$413K 0.04%
1,440
-784
-35% -$2.34K
YTEN
108
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$381K 0.03%
+224
New +$605K
GALT icon
109
PUT
Galectin Therapeutics
GALT
$223M
$378K 0.03%
1,131
+794
+236% +$2.01K
BPTH
110
DELISTED
Bio-Path Holdings Inc
BPTH
$371K 0.03%
+458
New +$589K
KA
111
DELISTED
Kineta, Inc. Common Stock
KA
$350K 0.03%
429
-644
-60% -$247K
VIRX
112
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$327K 0.03%
+25
New +$2.34K
SNES icon
113
SenesTech
SNES
$7.11M
$315K 0.03%
+9
New +$648K
NURO
114
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
$310K 0.03%
2,250
+1,080
+92% +$155K
ACHN
115
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
$286K 0.03%
992
– –
RXIIW
116
DELISTED
RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021
RXIIW
$273K 0.02%
2,100,797
– –
RGNX icon
117
CALL
Regenxbio
RGNX
$615M
$269K 0.02%
81
+3
+4% +$90
VTVT icon
118
vTv Therapeutics
VTVT
$122M
$267K 0.02%
1,113
-409
-27% -$91.7K
ONCS
119
DELISTED
OncoSec Medical Incorporated
ONCS
$249K 0.02%
696
-3,896
-85% -$1.36M
APDNW
120
DELISTED
Applied DNA Sciences Inc Warrant
APDNW
$244K 0.02%
642,289
-215,479
-25% -$120K
ABBV icon
121
CALL
AbbVie
ABBV
$465B
$242K 0.02%
25
-10,650
-100% -$1M
ONTXW
122
DELISTED
Onconova Therapeutics, Inc. Warrants
ONTXW
$225K 0.02%
643,244
-2,106
-0.3% -$1.25K
AIMT
123
DELISTED
Aimmune Therapeutics
AIMT
$213K 0.02%
+5,629
New +$182K
OPGN
124
DELISTED
OpGen, Inc
OPGN
$211K 0.02%
11
-6
-35% -$160K
SLS icon
125
CALL
SELLAS Life Sciences
SLS
$1.98B
$199K 0.02%
5
+1
+25% +$484
3 4
5
6 7

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2017 Portfolio in Review

As of Q4 2017, Sabby Management held 227 positions worth $1.1B, down 28% from $1.53B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sabby Management withdrew a net $290M in Q4 2017, closing 66 positions and reducing 51 holdings. Its most notable exit was GW Pharmaceuticals Plc American Depositary Shares, an estimated $3.35M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 12% of assets, up from 7.3% a quarter earlier, followed by Financials and Industrials.

Against the trend, Sabby Management opened a new position in Odonate Therapeutics, Inc. Common Stock worth $20.6M.

  • Sabby Management's largest Q4 2017 buy was Odonate Therapeutics, Inc. Common Stock: 825,451 shares worth $20.6M.
  • Sabby Management added most to Esperion Therapeutics in Q4 2017, an estimated $3.17M increase.
  • Sabby Management's biggest Q4 2017 reduction was Bristol-Myers Squibb, cutting an estimated $3.2M.
  • Sabby Management fully exited GW Pharmaceuticals Plc American Depositary Shares in Q4 2017, selling an estimated $3.35M.
  • Sabby Management's ten largest holdings make up 66% of its $1.1B portfolio in Q4 2017.
  • Sabby Management opened 63 new positions and closed 66 in Q4 2017.
  • Sabby Management's portfolio value fell 28% quarter-over-quarter to $1.1B.

Based on Sabby Management's 13F filing for Q4 2017, filed 14 Feb 2018.